Research on chronic lymphocytic leukemia (CLL) treatment is ongoing, with studies examining the effectiveness of various therapies, including triplet therapy and fixed-duration treatment. These new therapies may be improving outcomes for CLL patients, potentially allowing for more personalized treatment approaches. The impact of these treatments on progression-free survival and disease management is being explored in clinical settings and real-world studies.